Vomiting News and Research

RSS

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer.

7 Jan 2014

FDA accepts Cubist Pharmaceuticals' tedizolid phosphate NDA with Priority Review

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted the Company's New Drug Application for its investigational antibiotic tedizolid phosphate (TR-701) with Priority Review. The FDA has assigned a Prescription Drug User Fee Act action date of June 20, 2014. Cubist is seeking FDA approval of tedizolid for the treatment of acute bacterial skin and skin structure infections.

30 Dec 2013

Combination of medication and psychological therapy effective for treating chronic migraines in children

Psychological therapy plus medication appears to be the most effective treatment strategy for chronic migraine in children, but it may take time for the medical system to widely adopt this approach, says an editorial in the current issue of the Journal of the American Medical Association by Mark Connelly, PhD, a pain psychologist and co-director of the Comprehensive Headache Clinic at Children's Mercy Hospital.

26 Dec 2013

Antidepressant nortriptyline does not improve overall symptoms in patients with idiopathic gastroparesis

Among patients with idiopathic (of unknown cause) gastroparesis, use of the antidepressant nortriptyline compared with placebo for 15 weeks did not result in improvement in overall symptoms, according to a study appearing in the December 25 issue of JAMA.

25 Dec 2013

Scientists explore ways to tackle bacterium that causes diarrhea, vomiting, stomach pain

Scientists want to make a chink in the armor of a bacterium that has little name recognition yet is the number-one bacterial cause of the diarrhea, vomiting and stomach pain Americans experience annually.

20 Dec 2013

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

Baxter International Inc. today announced that the United States Food and Drug Administration granted approval of Baxter's FEIBA [Anti-Inhibitor Coagulant Complex], the first and only FDA-approved treatment for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors.

From Baxter International Inc. 20 Dec 2013

Anesthesiology residents want frequent feedback on clinical performance

Anesthesiology residents want frequent feedback on their clinical performance, as well as evaluations of their performance compared to their fellow residents as a whole, according to a study in the January issue of Anesthesiology.

19 Dec 2013

Helsinn, Mundipharma sign distribution and license agreement for investigational therapy

Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution agreement, covering China, Hong Kong and Macao, for netupitant-palonosetron fixed dose combination, a Helsinn product under development for the treatment of chemotherapy-induced nausea and vomiting.

19 Dec 2013

New legislation to provide epinephrine to children with severe food allergies in schools

An act recently signed by President Obama will make it easier to provide epinephrine to children with severe food allergies in schools, even without a prescription. Physicians at Nationwide Children's Hospital hope the act will encourage the remaining 20 states to pass legislation, incentivizing and, in some cases, requiring that schools to have this medication available for all students since up to 6 percent of children in the United States are now diagnosed with a food allergy.

17 Dec 2013

Pregnant women, infants should avoid unpasteurized milk products, urge pediatricians

Pregnant women, infants and young children should avoid raw or unpasteurized milk and milk products and only consume pasteurized products, according to a new policy statement from the American Academy of Pediatrics.

16 Dec 2013

Crealta to acquire all assets of Savient Pharmaceuticals

Savient Pharmaceuticals, Inc. ("Savient") announced that it has reached agreement on the terms of an acquisition agreement with Crealta Pharmaceuticals LLC ("Crealta") through which Crealta would acquire substantially all of the assets of Savient, including all KRYSTEXXA® assets, for gross proceeds of approximately $120.4 million.

11 Dec 2013

Antibody-toxin compound shows compelling antitumor activity in non-Hodgkin lymphomas patients

A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute.

11 Dec 2013

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics, Inc. today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA™) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013.

11 Dec 2013

Endocrinologist suggests parents to check their child's blood sugar more often during holidays

Indulgences abound during the holidays—from family gatherings to parties with friends and even stockings stuffed with goodies from Santa. For children with diabetes, overindulging on the delicacies of the season could result in more than a stomach ache, it could mean a trip to the emergency room.

10 Dec 2013

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative.

8 Dec 2013

EMA expands administration options for Hizentra

CSL Behring UK Ltd announced today that the European Medicines Agency (EMA) has expanded the administration options for Hizentra®▼, human normal immunoglobulin, SCIg, 20% liquid, to include dosing once every two weeks (fortnightly).

5 Dec 2013

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis will present updates on its broad cancer portfolio with more than 240 abstracts at the upcoming American Society of Hematology (ASH) annual meeting and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

4 Dec 2013

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease.

2 Dec 2013

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets.

27 Nov 2013

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Medicines Agency's: Committee for Medicinal Products for Human Use has adopted a positive opinion for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.

25 Nov 2013

Vomiting News and Research

Further Reading

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

FDA accepts Cubist Pharmaceuticals' tedizolid phosphate NDA with Priority Review

Combination of medication and psychological therapy effective for treating chronic migraines in children

Antidepressant nortriptyline does not improve overall symptoms in patients with idiopathic gastroparesis

Scientists explore ways to tackle bacterium that causes diarrhea, vomiting, stomach pain

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

Anesthesiology residents want frequent feedback on clinical performance

Helsinn, Mundipharma sign distribution and license agreement for investigational therapy

New legislation to provide epinephrine to children with severe food allergies in schools

Pregnant women, infants should avoid unpasteurized milk products, urge pediatricians

Crealta to acquire all assets of Savient Pharmaceuticals

Antibody-toxin compound shows compelling antitumor activity in non-Hodgkin lymphomas patients

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Endocrinologist suggests parents to check their child's blood sugar more often during holidays

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

EMA expands administration options for Hizentra

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Merck announces approval of NOXAFIL delayed-release tablets by FDA

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News